Treatment News : Single-Tablet Complera Combo Regimen Proves Comparable to Atripla

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 19, 2012

Single-Tablet Complera Combo Regimen Proves Comparable to Atripla

Complera proved to be “non-inferior” to, and in some cases more effective than, Atripla in a Phase IIIb study comparing the two single-pill, triple combination antiretroviral therapy regimens among treatment-naive people with HIV, the Business Wire reports. Gilead Sciences, which manufactures Complera (emtricitabine/rilpivirine/tenofovir) announced the findings from its STaR (Single Tablet Regimen) study at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow.

The study compared the rates of undetectable viral loads after 48 weeks of therapy between 394 participants taking Complera, which was approved in the United States in 2011, and another 392 taking Atripla (efavirenz/emtricitabine/tenofovir), the standard of care for treatment-naive people with HIV since its approval in 2006. Overall, 86 percent of those taking Complera and 82 percent of those on Atripla reached an undetectable viral load. Complera maintained a statistically significant advantage among those with a baseline viral load at or below 100,000, with 89 percent reaching undetectable compared with Atripla’s 82 percent. Meanwhile, 80 percent of Complera patients and 82 percent of Atripla patients with baseline viral loads above 100,000 achieved viral suppression.

To read the Business Wire report, click here.

To read Gilead’s release, click here.

Search: HIV, Complera, non-inferior, Atripla, comparble, Phase IIIb, emtricitabine, rilpivirine, tenofovir, STaR, Single Tablet Regimen, 11th International Congress on Drug Therapy in HIV Infection in Glasgow, undetectable viral load, viral suppression.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.